The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What factors influence the adoption rates of novel MM therapies in Latin America?
Featured:
Vania Tietsche de Moraes HungriaThe Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked: What factors influence the adoption rates of novel multiple myeloma (MM) therapies in Latin America?
What factors influence the adoption rates of novel MM therapies in Latin America?
In this video interview, Vania Hungria provides an overview of the MM landscape in Latin America, focusing on the differences in access and adoption of novel therapies in public and private health care facilities. Hungria discusses the distribution of treatment between public and private institutions and the outcomes associated with treatment in each type of center.